RXRX RECURSION PHARMACEUTICALS INC

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Disease Day event at its headquarters on February 29 and virtually in partnership with at eight sites across the United States to provide resources and support for Utah’s rare disease community. The event featured speakers from patient advocacy organizations and biotech and healthcare industry leaders who all share a goal to accelerate the diagnosis and improve the care of more than 344,000 Utahns living with a rare disease. 

In the United States, a rare disease is considered a condition with less than 200,000 patients. More than 10,000 rare diseases are known, most of which are genetic in nature. An estimated one in 10 people in the United States have a rare disease. Today, 95 percent of rare diseases have no treatment.

Recursion’s Rare Disease Day event was intended to raise awareness for rare and undiagnosed diseases and the lifelong impact they have on patients and their families – while highlighting progress in diagnosis and treatment discovery. The event recognized advocates who have been instrumental in building Utah’s rare disease community and have dedicated themselves to support this important work.

"This event serves as an important reminder of the strength, resilience and unrelenting spirit of our rare disease community here in Utah,” said Aimee Edwards, Executive Director of BioHive. “Through the power of our BioHive network of 1,600+ life science and healthcare companies in Utah, we aim to bring hope to patients and their families impacted by these conditions. We are proud of the formidable progress made and are fully dedicated to continuing our efforts until every unmet need in the rare disease community is addressed."

“There is an urgency for diagnoses, treatment and cures for the rare disease community,” said Gina Zanik, co-founder and executive director of Rare and Undiagnosed Network and Vice Chair of the Utah Rare Disease Advisory Council. “The diagnostic odyssey for someone with a rare disease takes on average seven years. We must shorten the length of the diagnostic journey and come together to support patients and their families throughout the duration.”

Rare Disease Day is an annual observance on the last day of February. A series of events were held globally to raise awareness, strengthen the rare disease community, and advocate for needed changes to improve the lives of the 400 million people around the world who suffer from these conditions.

Rare disease patients came together at Recursion with the (RUN), , , , , the and the (RDAC) for the Rare Disease Day event. The coalition of organizations represents Utah’s strong collaborative ecosystem dedicated to coordinating, advocating, and promoting the interest of those living with rare diseases.

“Recursion was founded to reimagine the drug discovery and development process with an early focus on rare diseases,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “The status quo is failing to meet the needs of millions of patients with rare diseases. The rapidly growing TechBio industry is harnessing technologies like artificial intelligence to accelerate the process of bringing more, better medicines to patients who need them.”

About Recursion

is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine. 

Recursion is headquartered in Salt Lake City, where it is a founding member of , the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at , or connect on (formerlyTwitter) and .

Attachment



Media Contact
 

Investor Contact
 
EN
01/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates...

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)ear...

 PRESS RELEASE

Recursion Reports Grant of Inducement Awards as Permitted by the Nasda...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award w...

 PRESS RELEASE

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will also participate in the following upcoming investor conference: 28th Annual Needham Growth Conference - Friday, January 16, 2026 Webcasts may be found in th...

 PRESS RELEASE

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonst...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of unt...

 PRESS RELEASE

Recursion Announces Webinar For Upcoming Clinical Data Readout on the ...

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recurs...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch